European regulators launch speedier drug approval process: AbbVie and Boehringer Ingelheim to partner on psoriasis drug; the FDA approves hemophilia B drug
Five things for pharma marketers to know: Tuesday, July 21
Physicians criticize pricing of Orkambi, Vertex’s new cystic-fibrosis drug; the EU approves Amgen’s PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
Five things for pharma marketers to know: Friday, March 27
Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system
Scotland’s NICE dislikes GSK’s Anoro
August 11, 2014
5:54 pm
The Scottish Medicines Consortium gave a thumb’s down to GSK’s drug and a Boehringer COPD drug.
Britain’s National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche’s breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Loading...
MM+M Transform: The Patient, Provider and Payer Engagement Matrix